Eculizumab in Atypical Hemolytic-Uremic Syndrome

To the Editor: With regard to the article by Legendre et al. (June 6 issue)(1): assessment of the 37 patients with atypical hemolytic-uremic syndrome is difficult, since the process of selection seems opaque, particularly for the 20 patients in trial 2. It would have been beneficial to have these patients undergo randomization, given the fluctuating, relapsing nature of the underlying disease. In trial 1, a shorter delay before administration of the first dose of eculizumab was reported to result in a better recovery of renal function. My colleagues and I evaluated these data with consideration of the delay before . . .